Cassiopeia study myeloma
Web16 Mar 2024 · Multiple myeloma (MM) accounts for 15% of all hematologic malignancies, with an estimated 34,920 new cases in 2024 [1,2,3,4].The treatment approach to MM involves use of multidrug combinations and ... WebThe Multiple Myeloma Hub has previously published the findings of CASSIOPEIA Part 1, a phase III randomized controlled trial in patients with newly diagnosed multiple myeloma (NDMM) comparing daratumumab, an anti-CD38 antibody, in combination with bortezomib, thalidomide and dexamethasone (D-VTd) to bortezomib, thalidomide, and …
Cassiopeia study myeloma
Did you know?
Web19 Feb 2024 · Indeed, much of the most recent evidence that informs current standard practice stems from the large EMN02, IFM2009, and CASSIOPEIA randomized studies in MM patients with de novo disease eligible for ASCT. 3, 6, 7 These studies employed 3 different induction protocols: 3–4 cycles of VCD in EMN02, 3 cycles of VRD in IFM2009, … Web8 Aug 2024 · CONSORT diagram for the CASSIOPEIA study. The study flow diagram is shown for the CASSIOPEIA study from first randomization through completion of autologous stem cell transplant. ... with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a …
Web28 Mar 2024 · The CASSIOPEIA phase 3 study included 1085 NDMM ... with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a ... Web14 Nov 2024 · While CASSIOPEIA had several hundred patients, 7 GRIFFIN only had a little over [100] patients in each arm. 9 At 24 months, the PFS remains very high in both arms, and the same [is true] for OS, [although the data are] not mature yet. Of course, with the addition of agents, toxicity increases.
Web13 Sep 2024 · CASSIOPEIA, a two-part, phase 3 trial, has brought daratumumab to the forefront of efforts aimed at improving outcome for transplant-eligible patients. Part 1 … Web13 Jun 2024 · CASSIOPEIA is a 2-part study; the second part of this trial will randomize patients to receive either daratumumab maintenance or no maintenance. The second phase of the trial is currently ongoing and the researchers expect that a long follow-up is needed.
Web31 Dec 2015 · The CASSIOPEIA trial IFM / HOVON IFM 2015-01 HOVON HO131 MM Newly Diagnosed Multiple Myeloma A Study to Evaluate Daratumumab in Transplant Eligible …
Webdiagnosed multiple myeloma, but overall survival results were mixed, and rates of second primary malignancies were increased compared with placebo or observation. Added value of this study. To our knowledge, part 2 of the CASSIOPEIA study is the first randomised controlled trial of daratumumab as maintenance phenothiazine cas noWebDVTd: CASSIOPEIA (Transplant-eligible) DARZALEX® in relapsed or refractory multiple myeloma DRd: POLLUX For relapsed or refractory multiple myeloma, after 1 prior … phenothiazine classWebIn a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induceda very good partial response or better rate of 42% and was well tolerated in … phenothiazine cross reactivityphenothiazine conjugatedWeb23 Mar 2024 · Multiple myeloma is a hematologic cancer in which clonal plasma-cell proliferation leads to complications and death. 1 Initial treatment for newly diagnosed multiple myeloma depends on whether a ... phenothiazine drug classWeb13 Sep 2024 · Daratumumab, a potent CD38-directed monoclonal antibody, has veritably transformed the treatment landscape of multiple myeloma. CASSIOPEIA, a two-part, phase 3 trial, has brought daratumumab to the forefront of efforts aimed at improving outcome for transplant-eligible patients. phenothiazine chlorideWeb9 Jun 2024 · Daratumumab (DARA) and Velcade (bortezomib)/thalidomide/ dexamethasone (DVTd) plus autologous stem cell transplant (ASCT) was approved for transplant-eligible … phenothiazine drug classification